Emiplacel

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameEmiplacel
Drug Alias NameAllogeneic ex-vivo expanded placental adherent stromal cellsPLX-PAD cell therapyPLacental eXpanded cellsPLX-PAD
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Placenta-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionCell differentiation modulatorsCell replacementsDendritic cells modulators
TargetsNot applicable
Therapy Area/IndicationsMuscle injuryHip FracturesIschemia +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBerlin-Brandenburg Center For Regenerative TherapiesPluristem Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBar Ilan UniversityPluristem Ltd
Inactive CompaniesUnited Therapeutics Corp
Active IndicationsHip FracturesIschemia
Inactive IndicationsMuscle injuryPeripheral Vascular DiseasesIntermittent Claudication +[7] 

Other Information

ATC CodeN/A
Related LinksN/A